{"id":"NCT03303092","sponsor":"Otsuka Pharmaceutical Co., Ltd.","briefTitle":"Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial Evaluating the Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2017-12-19","primaryCompletion":"2019-11-22","completion":"2019-11-22","firstPosted":"2017-10-05","resultsPosted":"2021-07-08","lastUpdate":"2021-07-29"},"enrollment":357,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Migraine"],"interventions":[{"type":"DRUG","name":"TEV-48125","otherNames":[]},{"type":"DRUG","name":"TEV-48125 or placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TEV-48125 (225/225/225 mg) group","type":"EXPERIMENTAL"},{"label":"TEV-48125 (675 mg/placebo/placebo) group","type":"EXPERIMENTAL"},{"label":"Placebo group","type":"PLACEBO_COMPARATOR"}],"summary":"To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 (monthly TEV-48125 225 mg and TEV-48125 675 mg once over a period of 3 months) compared with placebo for preventive treatment in Episodic Migraine patients","primaryOutcome":{"measure":"Mean Change From Baseline in the Monthly (28 Days) Average Number of Migraine Days During the 12-week Period After the First Dose of Investigational Medicinal Product (IMP)","timeFrame":"Baseline, 12 weeks","effectByArm":[{"arm":"TEV-48125 (225/225/225 mg) Group","deltaMin":-4,"sd":0.37},{"arm":"TEV-48125 (675 mg/Placebo/Placebo) Group","deltaMin":-4.02,"sd":0.38},{"arm":"Placebo Group","deltaMin":-1.02,"sd":0.38}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":null},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["35139816"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":121},"commonTop":["Injection site erythema","Nasopharyngitis","Injection site induration","Injection site pain","Injection site pruritus"]}}